AU2007221135A1 - Methods for regulating neurotransmitter systems by inducing counteradaptations - Google Patents

Methods for regulating neurotransmitter systems by inducing counteradaptations Download PDF

Info

Publication number: AU2007221135A1
Authority: AU; Australia
Prior art keywords: administration; receptors; receptor; ligand; neurological
Prior art date: 2006-02-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2007221135A

Other languages

English (en)

Inventor

Alexander Michalow

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-27

Filing date

2007-02-27

Publication date

2007-09-07

2007-02-27 Application filed by Individual filed Critical Individual

2007-09-07 Publication of AU2007221135A1 publication Critical patent/AU2007221135A1/en

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 508
239000002858 neurotransmitter agent Substances 0.000 title claims description 127
230000001939 inductive effect Effects 0.000 title claims description 16
230000001105 regulatory effect Effects 0.000 title claims description 16
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 298
102000005962 receptors Human genes 0.000 claims description 281
108020003175 receptors Proteins 0.000 claims description 281
239000003446 ligand Substances 0.000 claims description 211
229940076279 serotonin Drugs 0.000 claims description 149
230000003340 mental effect Effects 0.000 claims description 141
230000000926 neurological effect Effects 0.000 claims description 129
230000000694 effects Effects 0.000 claims description 122
230000004962 physiological condition Effects 0.000 claims description 120
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 119
229960002748 norepinephrine Drugs 0.000 claims description 119
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 119
229940044601 receptor agonist Drugs 0.000 claims description 112
239000000018 receptor agonist Substances 0.000 claims description 112
102100021752 Corticoliberin Human genes 0.000 claims description 97
230000001242 postsynaptic effect Effects 0.000 claims description 97
239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 95
230000003518 presynaptic effect Effects 0.000 claims description 94
230000027455 binding Effects 0.000 claims description 88
150000001875 compounds Chemical class 0.000 claims description 86
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 80
239000000556 agonist Substances 0.000 claims description 75
239000005557 antagonist Substances 0.000 claims description 74
230000007423 decrease Effects 0.000 claims description 71
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 69
108010049140 Endorphins Proteins 0.000 claims description 66
102000009025 Endorphins Human genes 0.000 claims description 66
230000001965 increasing effect Effects 0.000 claims description 65
102000007527 Autoreceptors Human genes 0.000 claims description 61
108010071131 Autoreceptors Proteins 0.000 claims description 61
239000000857 delta opiate receptor antagonist Substances 0.000 claims description 61
208000002193 Pain Diseases 0.000 claims description 59
229960004127 naloxone Drugs 0.000 claims description 58
239000002623 mu opiate receptor antagonist Substances 0.000 claims description 57
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 57
108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 claims description 52
239000002464 receptor antagonist Substances 0.000 claims description 51
229940044551 receptor antagonist Drugs 0.000 claims description 51
230000036407 pain Effects 0.000 claims description 46
230000004044 response Effects 0.000 claims description 41
150000003839 salts Chemical class 0.000 claims description 37
230000035945 sensitivity Effects 0.000 claims description 37
208000019901 Anxiety disease Diseases 0.000 claims description 35
101800001144 Arg-vasopressin Proteins 0.000 claims description 35
108010065372 Dynorphins Proteins 0.000 claims description 35
230000003828 downregulation Effects 0.000 claims description 35
239000002632 kappa opiate receptor agonist Substances 0.000 claims description 35
-1 L-733060 Chemical compound 0.000 claims description 34
102400000059 Arg-vasopressin Human genes 0.000 claims description 33
230000003827 upregulation Effects 0.000 claims description 33
230000008901 benefit Effects 0.000 claims description 32
108090000765 processed proteins & peptides Proteins 0.000 claims description 31
102000003840 Opioid Receptors Human genes 0.000 claims description 29
108090000137 Opioid Receptors Proteins 0.000 claims description 29
230000015572 biosynthetic process Effects 0.000 claims description 29
102100024622 Proenkephalin-B Human genes 0.000 claims description 28
239000003795 chemical substances by application Substances 0.000 claims description 28
208000019022 Mood disease Diseases 0.000 claims description 25
201000009032 substance abuse Diseases 0.000 claims description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
208000035475 disorder Diseases 0.000 claims description 24
102100024304 Protachykinin-1 Human genes 0.000 claims description 23
229960003086 naltrexone Drugs 0.000 claims description 23
230000001225 therapeutic effect Effects 0.000 claims description 23
238000011282 treatment Methods 0.000 claims description 22
238000002560 therapeutic procedure Methods 0.000 claims description 21
239000002249 anxiolytic agent Substances 0.000 claims description 20
230000033228 biological regulation Effects 0.000 claims description 20
102000048260 kappa Opioid Receptors Human genes 0.000 claims description 20
208000024714 major depressive disease Diseases 0.000 claims description 20
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 20
108020001588 κ-opioid receptors Proteins 0.000 claims description 20
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims description 19
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims description 19
210000000987 immune system Anatomy 0.000 claims description 19
108060003345 Adrenergic Receptor Proteins 0.000 claims description 18
102000017910 Adrenergic receptor Human genes 0.000 claims description 18
208000030814 Eating disease Diseases 0.000 claims description 18
208000019454 Feeding and Eating disease Diseases 0.000 claims description 18
206010028980 Neoplasm Diseases 0.000 claims description 18
230000036506 anxiety Effects 0.000 claims description 18
201000011510 cancer Diseases 0.000 claims description 18
235000014632 disordered eating Nutrition 0.000 claims description 18
208000011117 substance-related disease Diseases 0.000 claims description 17
239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims description 16
239000000674 adrenergic antagonist Substances 0.000 claims description 16
239000002769 corticotropin releasing factor antagonist Substances 0.000 claims description 16
239000003401 opiate antagonist Substances 0.000 claims description 16
231100000736 substance abuse Toxicity 0.000 claims description 16
125000001183 hydrocarbyl group Chemical group 0.000 claims description 15
239000000126 substance Substances 0.000 claims description 15
LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims description 14
239000000048 adrenergic agonist Substances 0.000 claims description 14
230000001684 chronic effect Effects 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 14
238000009472 formulation Methods 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 14
229940002612 prodrug Drugs 0.000 claims description 14
239000000651 prodrug Substances 0.000 claims description 14
OBSYBRPAKCASQB-UHFFFAOYSA-N Episalvinorin A Natural products COC(=O)C1CC(OC(C)=O)C(=O)C(C2(C3)C)C1(C)CCC2C(=O)OC3C=1C=COC=1 OBSYBRPAKCASQB-UHFFFAOYSA-N 0.000 claims description 13
101800003906 Substance P Proteins 0.000 claims description 13
229940126157 adrenergic receptor agonist Drugs 0.000 claims description 13
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical group C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 13
IQXUYSXCJCVVPA-UHFFFAOYSA-N salvinorin A Natural products CC(=O)OC1CC(OC(=O)C)C2(C)CCC34CC(CC3(C)C2C1=O)(OC4=O)c5occc5 IQXUYSXCJCVVPA-UHFFFAOYSA-N 0.000 claims description 13
OBSYBRPAKCASQB-AGQYDFLVSA-N salvinorin A Chemical group C=1([C@H]2OC(=O)[C@@H]3CC[C@]4(C)[C@@H]([C@]3(C2)C)C(=O)[C@@H](OC(C)=O)C[C@H]4C(=O)OC)C=COC=1 OBSYBRPAKCASQB-AGQYDFLVSA-N 0.000 claims description 13
101800000399 Neurokinin A Proteins 0.000 claims description 12
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
210000003016 hypothalamus Anatomy 0.000 claims description 12
230000008450 motivation Effects 0.000 claims description 12
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical group C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 11
208000020925 Bipolar disease Diseases 0.000 claims description 11
201000001880 Sexual dysfunction Diseases 0.000 claims description 11
230000000949 anxiolytic effect Effects 0.000 claims description 11
201000003995 melancholia Diseases 0.000 claims description 11
239000004081 narcotic agent Substances 0.000 claims description 11
231100000872 sexual dysfunction Toxicity 0.000 claims description 11
230000000946 synaptic effect Effects 0.000 claims description 11
206010002942 Apathy Diseases 0.000 claims description 10
101710113174 Corticoliberin Proteins 0.000 claims description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
206010020710 Hyperphagia Diseases 0.000 claims description 10
230000003466 anti-cipated effect Effects 0.000 claims description 10
208000025748 atypical depressive disease Diseases 0.000 claims description 10
230000001363 autoimmune Effects 0.000 claims description 10
239000000380 hallucinogen Substances 0.000 claims description 10
230000028252 learning or memory Effects 0.000 claims description 10
235000020830 overeating Nutrition 0.000 claims description 10
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 9
JMBYBVLCYODBJQ-HFMPRLQTSA-N 2-(1-benzofuran-4-yl)-n-methyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=3C=COC=3C=CC=2)C[C@]21CCCO2 JMBYBVLCYODBJQ-HFMPRLQTSA-N 0.000 claims description 9
208000008035 Back Pain Diseases 0.000 claims description 9
206010058019 Cancer Pain Diseases 0.000 claims description 9
244000025254 Cannabis sativa Species 0.000 claims description 9
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 9
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 9
206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 9
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 9
206010012374 Depressed mood Diseases 0.000 claims description 9
208000001640 Fibromyalgia Diseases 0.000 claims description 9
101800002813 Neurokinin-B Proteins 0.000 claims description 9
208000008589 Obesity Diseases 0.000 claims description 9
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 9
239000002246 antineoplastic agent Substances 0.000 claims description 9
229940005530 anxiolytics Drugs 0.000 claims description 9
239000003874 central nervous system depressant Substances 0.000 claims description 9
229950010961 enadoline Drugs 0.000 claims description 9
230000004060 metabolic process Effects 0.000 claims description 9
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 9
201000001119 neuropathy Diseases 0.000 claims description 9
230000007823 neuropathy Effects 0.000 claims description 9
229960002715 nicotine Drugs 0.000 claims description 9
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 9
235000020824 obesity Nutrition 0.000 claims description 9
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 9
239000000021 stimulant Substances 0.000 claims description 9
230000035882 stress Effects 0.000 claims description 9
208000007415 Anhedonia Diseases 0.000 claims description 8
208000021500 Breathing-related sleep disease Diseases 0.000 claims description 8
208000032841 Bulimia Diseases 0.000 claims description 8
206010006550 Bulimia nervosa Diseases 0.000 claims description 8
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
206010019233 Headaches Diseases 0.000 claims description 8
208000007514 Herpes zoster Diseases 0.000 claims description 8
208000004356 Hysteria Diseases 0.000 claims description 8
206010065390 Inflammatory pain Diseases 0.000 claims description 8
206010028813 Nausea Diseases 0.000 claims description 8
102000004108 Neurotransmitter Receptors Human genes 0.000 claims description 8
108090000590 Neurotransmitter Receptors Proteins 0.000 claims description 8
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 8
208000000323 Tourette Syndrome Diseases 0.000 claims description 8
208000016620 Tourette disease Diseases 0.000 claims description 8
206010047700 Vomiting Diseases 0.000 claims description 8
208000022531 anorexia Diseases 0.000 claims description 8
230000000386 athletic effect Effects 0.000 claims description 8
229960002495 buspirone Drugs 0.000 claims description 8
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 8
208000022371 chronic pain syndrome Diseases 0.000 claims description 8
208000012839 conversion disease Diseases 0.000 claims description 8
206010061428 decreased appetite Diseases 0.000 claims description 8
JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 claims description 8
208000024732 dysthymic disease Diseases 0.000 claims description 8
208000037870 generalized anxiety Diseases 0.000 claims description 8
229960000647 gepirone Drugs 0.000 claims description 8
QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 claims description 8
AHCPKWJUALHOPH-UHFFFAOYSA-N lesopitron Chemical compound C1=C(Cl)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 AHCPKWJUALHOPH-UHFFFAOYSA-N 0.000 claims description 8
229950001590 lesopitron Drugs 0.000 claims description 8
230000008693 nausea Effects 0.000 claims description 8
208000019906 panic disease Diseases 0.000 claims description 8
208000033808 peripheral neuropathy Diseases 0.000 claims description 8
208000019116 sleep disease Diseases 0.000 claims description 8
CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims description 8
229950000505 tandospirone Drugs 0.000 claims description 8
AERLHOTUXIJQFV-RCPZPFRWSA-N zalospirone Chemical compound O=C([C@@H]1[C@@H]([C@@H]2C=C[C@H]1[C@H]1C=C[C@H]12)C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 AERLHOTUXIJQFV-RCPZPFRWSA-N 0.000 claims description 8
229950005255 zalospirone Drugs 0.000 claims description 8
206010062767 Hypophysitis Diseases 0.000 claims description 7
PGZRDDYTKFZSFR-ONTIZHBOSA-N U69593 Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=CC=CC=2)C[C@]21CCCO2 PGZRDDYTKFZSFR-ONTIZHBOSA-N 0.000 claims description 7
238000011161 development Methods 0.000 claims description 7
230000018109 developmental process Effects 0.000 claims description 7
229940079593 drug Drugs 0.000 claims description 7
230000015654 memory Effects 0.000 claims description 7
XGZZHZMWIXFATA-UEZBDDGYSA-N nalfurafine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3N(C)C(=O)\C=C\C1=COC=C1)CN2CC1CC1 XGZZHZMWIXFATA-UEZBDDGYSA-N 0.000 claims description 7
229960000441 nalfurafine Drugs 0.000 claims description 7
230000037361 pathway Effects 0.000 claims description 7
210000003635 pituitary gland Anatomy 0.000 claims description 7
PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical group C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 claims description 7
238000012360 testing method Methods 0.000 claims description 7
RLHGFJMGWQXPBW-UHFFFAOYSA-N 2-hydroxy-3-(1h-imidazol-5-ylmethyl)benzamide Chemical compound NC(=O)C1=CC=CC(CC=2NC=NC=2)=C1O RLHGFJMGWQXPBW-UHFFFAOYSA-N 0.000 claims description 6
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 6
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 6
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 6
INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 6
208000027418 Wounds and injury Diseases 0.000 claims description 6
208000005298 acute pain Diseases 0.000 claims description 6
239000003443 antiviral agent Substances 0.000 claims description 6
229940049706 benzodiazepine Drugs 0.000 claims description 6
229960002896 clonidine Drugs 0.000 claims description 6
JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 claims description 6
229960001894 detomidine Drugs 0.000 claims description 6
HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 claims description 6
229960004253 dexmedetomidine Drugs 0.000 claims description 6
229960002048 guanfacine Drugs 0.000 claims description 6
HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical group N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 claims description 6
229950001476 idazoxan Drugs 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
150000002632 lipids Chemical class 0.000 claims description 6
229960005209 lofexidine Drugs 0.000 claims description 6
KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 claims description 6
229950010998 mivazerol Drugs 0.000 claims description 6
229960005297 nalmefene Drugs 0.000 claims description 6
230000037081 physical activity Effects 0.000 claims description 6
208000028173 post-traumatic stress disease Diseases 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
206010037844 rash Diseases 0.000 claims description 6
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 6
238000012549 training Methods 0.000 claims description 6
230000000472 traumatic effect Effects 0.000 claims description 6
RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical group Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 claims description 6
235000019786 weight gain Nutrition 0.000 claims description 6
FLNYLINBEZROPL-NSOVKSMOSA-N (2s,3s)-2-benzhydryl-n-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 FLNYLINBEZROPL-NSOVKSMOSA-N 0.000 claims description 5
XIGAHNVCEFUYOV-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-BTJKTKAUSA-N 0.000 claims description 5
ZLNYUCXXSDDIFU-LJAQVGFWSA-N 2-[1-[2-[(2r)-4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)morpholin-2-yl]ethyl]piperidin-4-yl]-2-methylpropanamide Chemical compound C1CC(C(C)(C)C(N)=O)CCN1CC[C@]1(C=2C=C(Cl)C(Cl)=CC=2)OCCN(C(=O)CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C1 ZLNYUCXXSDDIFU-LJAQVGFWSA-N 0.000 claims description 5
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
ANNRUWYFVIGKHA-UHFFFAOYSA-N 3-[6-(dimethylamino)-4-methylpyridin-3-yl]-2,5-dimethyl-n,n-dipropylpyrazolo[1,5-a]pyrimidin-7-amine Chemical compound CC1=NN2C(N(CCC)CCC)=CC(C)=NC2=C1C1=CN=C(N(C)C)C=C1C ANNRUWYFVIGKHA-UHFFFAOYSA-N 0.000 claims description 5
MDWRPTOUDPFXKK-UHFFFAOYSA-N 8-(2,4-dichlorophenyl)-n-(1,3-dimethoxypropan-2-yl)-2,7-dimethylpyrazolo[1,5-a][1,3,5]triazin-4-amine Chemical compound CC1=NN2C(NC(COC)COC)=NC(C)=NC2=C1C1=CC=C(Cl)C=C1Cl MDWRPTOUDPFXKK-UHFFFAOYSA-N 0.000 claims description 5
IEAKXXNRGSLYTQ-DEOSSOPVSA-N SSR 125543 Chemical compound C1=C(C)C(OC)=CC(Cl)=C1C1=C(C)SC(N(CC#C)[C@@H](CC2CC2)C=2C=C(F)C(C)=CC=2)=N1 IEAKXXNRGSLYTQ-DEOSSOPVSA-N 0.000 claims description 5
208000027520 Somatoform disease Diseases 0.000 claims description 5
102100033009 Tachykinin-3 Human genes 0.000 claims description 5
206010046543 Urinary incontinence Diseases 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 5
IXPROWGEHNVJOY-UHFFFAOYSA-N antalarmin Chemical compound CC1=C(C)C=2C(N(CC)CCCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C IXPROWGEHNVJOY-UHFFFAOYSA-N 0.000 claims description 5
239000004599 antimicrobial Substances 0.000 claims description 5
ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 5
108010063987 astressin Proteins 0.000 claims description 5
HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 5
FHQYJZCJRZHINA-UHFFFAOYSA-N cp-154,526 Chemical compound C1=C(C)C=2C(N(CC)CCCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C FHQYJZCJRZHINA-UHFFFAOYSA-N 0.000 claims description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 5
229960003529 diazepam Drugs 0.000 claims description 5
NXLUTEDAEFXMQR-BJKOFHAPSA-N n-[(2r,4s)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2[C@@H](C[C@H](CC2)NC(=O)C=2C3=CC=CC=C3N=CC=2)CC=2C=CC(Cl)=CC=2)=C1 NXLUTEDAEFXMQR-BJKOFHAPSA-N 0.000 claims description 5
KSNUCNRMDYJBKT-UHFFFAOYSA-N n-[3-[4-[4-(2-oxo-3,4-dihydroquinolin-1-yl)piperidine-1-carbonyl]phenoxy]propyl]acetamide Chemical compound C1=CC(OCCCNC(=O)C)=CC=C1C(=O)N1CCC(N2C3=CC=CC=C3CCC2=O)CC1 KSNUCNRMDYJBKT-UHFFFAOYSA-N 0.000 claims description 5
DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 claims description 5
208000027753 pain disease Diseases 0.000 claims description 5
230000004584 weight gain Effects 0.000 claims description 5
XUWLAGNFLUARAN-CHQNGUEUSA-N (2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-2-methylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)C(C)(C)NC(=O)C(C)(C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)N(CC=C)CC=C)C1=CC=CC=C1 XUWLAGNFLUARAN-CHQNGUEUSA-N 0.000 claims description 4
XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 claims description 4
DTQNEFOKTXXQKV-HKUYNNGSSA-N (2s,3s)-n-[(2-methoxyphenyl)methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=CC=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 DTQNEFOKTXXQKV-HKUYNNGSSA-N 0.000 claims description 4
ZIWFCOIGUNPHPM-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 ZIWFCOIGUNPHPM-HKUYNNGSSA-N 0.000 claims description 4
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims description 4
ABTNETSDXZBJTE-WLHGVMLRSA-N (e)-but-2-enedioic acid;methyl 4-[2-(3,4-dichlorophenyl)acetyl]-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate Chemical compound OC(=O)\C=C\C(O)=O.C1N(C(=O)OC)CCN(C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C1CN1CCCC1 ABTNETSDXZBJTE-WLHGVMLRSA-N 0.000 claims description 4
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 claims description 4
108091005482 5-HT4 receptors Proteins 0.000 claims description 4
108091005435 5-HT6 receptors Proteins 0.000 claims description 4
108091005436 5-HT7 receptors Proteins 0.000 claims description 4
JXBLEDCYKVWLJI-UHFFFAOYSA-N 8-[2-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)ethyl]-8-azaspiro[4.5]decane-7,9-dione;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1C(=O)N(CCNCC2OC3=CC=CC=C3OC2)C(=O)CC21CCCC2 JXBLEDCYKVWLJI-UHFFFAOYSA-N 0.000 claims description 4
102100034159 Beta-3 adrenergic receptor Human genes 0.000 claims description 4
208000000094 Chronic Pain Diseases 0.000 claims description 4
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 4
108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 4
101800000637 Hemokinin Proteins 0.000 claims description 4
239000005517 L01XE01 - Imatinib Substances 0.000 claims description 4
SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 claims description 4
101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 claims description 4
229940084576 Neurotransmitter agonist Drugs 0.000 claims description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 claims description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims description 4
230000032683 aging Effects 0.000 claims description 4
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 4
229960004538 alprazolam Drugs 0.000 claims description 4
229940034982 antineoplastic agent Drugs 0.000 claims description 4
235000019789 appetite Nutrition 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
108040005346 beta3-adrenergic receptor activity proteins Proteins 0.000 claims description 4
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
229960004630 chlorambucil Drugs 0.000 claims description 4
229960000562 conivaptan Drugs 0.000 claims description 4
VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
229960004397 cyclophosphamide Drugs 0.000 claims description 4
229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 4
229940088598 enzyme Drugs 0.000 claims description 4
201000005884 exanthem Diseases 0.000 claims description 4
SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 claims description 4
229960003528 flurazepam Drugs 0.000 claims description 4
238000001415 gene therapy Methods 0.000 claims description 4
239000003326 hypnotic agent Substances 0.000 claims description 4
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 4
239000007943 implant Substances 0.000 claims description 4
230000004968 inflammatory condition Effects 0.000 claims description 4
239000003112 inhibitor Substances 0.000 claims description 4
229950003599 ipsapirone Drugs 0.000 claims description 4
239000002618 kappa opiate receptor antagonist Substances 0.000 claims description 4
229960004391 lorazepam Drugs 0.000 claims description 4
239000003094 microcapsule Substances 0.000 claims description 4
IYNWSQDZXMGGGI-UHFFFAOYSA-N morphinan-3-ol Chemical compound C1CCCC2C3CC4=CC=C(O)C=C4C21CCN3 IYNWSQDZXMGGGI-UHFFFAOYSA-N 0.000 claims description 4
WRNXUQJJCIZICJ-UHFFFAOYSA-N mozavaptan Chemical compound C12=CC=CC=C2C(N(C)C)CCCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C WRNXUQJJCIZICJ-UHFFFAOYSA-N 0.000 claims description 4
KXMAIWXPZGQNCR-QGZVFWFLSA-N n-propyl-10-[(2r)-1-pyrrolidin-1-ylpropan-2-yl]phenothiazine-2-carboxamide Chemical compound C([C@@H](C)N1C2=CC=CC=C2SC2=CC=C(C=C21)C(=O)NCCC)N1CCCC1 KXMAIWXPZGQNCR-QGZVFWFLSA-N 0.000 claims description 4
NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 4
229960000805 nalbuphine Drugs 0.000 claims description 4
230000003204 osmotic effect Effects 0.000 claims description 4
208000019899 phobic disease Diseases 0.000 claims description 4
229950004387 saredutant Drugs 0.000 claims description 4
239000003890 substance P antagonist Substances 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
229960003188 temazepam Drugs 0.000 claims description 4
229960002555 zidovudine Drugs 0.000 claims description 4
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 4
LJGOZJHDEQHJRI-SITYYSIOSA-N α-helical crf Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(C)C)C1=CNC=N1 LJGOZJHDEQHJRI-SITYYSIOSA-N 0.000 claims description 4
FCDRFVCGMLUYPG-ROUUACIJSA-N (2S,3S)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CO[C@@H]2[C@@H](NCCC2)C=2C=CC=CC=2)=C1 FCDRFVCGMLUYPG-ROUUACIJSA-N 0.000 claims description 3
RMYPEYHEPIZYDJ-SNVBAGLBSA-N (2r)-2-azaniumyl-3-(4-ethoxyphenyl)propanoate Chemical compound CCOC1=CC=C(C[C@@H](N)C(O)=O)C=C1 RMYPEYHEPIZYDJ-SNVBAGLBSA-N 0.000 claims description 3
CZRZYRKTYLLLRL-DTXPUJKBSA-N (2s)-2-[[(2s)-2-[2-[[2-[[(2s)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]ethylsulfanyl]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)SCCNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)N(CC=C)CC=C)C1=CC=CC=C1 CZRZYRKTYLLLRL-DTXPUJKBSA-N 0.000 claims description 3
YLVSTHFZZCHRCL-ORUZXOCWSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]am Chemical compound CSCC[C@@H](C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)CC1=CC=CC=C1 YLVSTHFZZCHRCL-ORUZXOCWSA-N 0.000 claims description 3
VUSNBQDZGKZEDL-UHFFFAOYSA-N 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-4-phenylpiperazine Chemical compound C=1C=C2OCOC2=CC=1OCCCN(CC1)CCN1C1=CC=CC=C1 VUSNBQDZGKZEDL-UHFFFAOYSA-N 0.000 claims description 3
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 3
BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 claims description 3
108091005477 5-HT3 receptors Proteins 0.000 claims description 3
WXOUFNFMPVMGFZ-BDQAUFNLSA-N 7-Benzylidenenaltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC(/C5=O)=C\C=2C=CC=CC=2)O)CC1)O)CC1CC1 WXOUFNFMPVMGFZ-BDQAUFNLSA-N 0.000 claims description 3
208000030507 AIDS Diseases 0.000 claims description 3
101100289888 Caenorhabditis elegans lys-5 gene Proteins 0.000 claims description 3
206010010741 Conjunctivitis Diseases 0.000 claims description 3
201000004624 Dermatitis Diseases 0.000 claims description 3
206010015150 Erythema Diseases 0.000 claims description 3
208000010201 Exanthema Diseases 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
206010024264 Lethargy Diseases 0.000 claims description 3
201000010927 Mucositis Diseases 0.000 claims description 3
206010033645 Pancreatitis Diseases 0.000 claims description 3
206010033647 Pancreatitis acute Diseases 0.000 claims description 3
201000003229 acute pancreatitis Diseases 0.000 claims description 3
229940121375 antifungal agent Drugs 0.000 claims description 3
239000003429 antifungal agent Substances 0.000 claims description 3
230000036528 appetite Effects 0.000 claims description 3
210000004899 c-terminal region Anatomy 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
238000002512 chemotherapy Methods 0.000 claims description 3
108010038267 cortagine Proteins 0.000 claims description 3
239000000841 delta opiate receptor agonist Substances 0.000 claims description 3
JMBYBVLCYODBJQ-UHFFFAOYSA-N enadoline Chemical compound C=1C=CC=2OC=CC=2C=1CC(=O)N(C)C(C(C1)N2CCCC2)CCC21CCCO2 JMBYBVLCYODBJQ-UHFFFAOYSA-N 0.000 claims description 3
231100000321 erythema Toxicity 0.000 claims description 3
206010016256 fatigue Diseases 0.000 claims description 3
230000035876 healing Effects 0.000 claims description 3
108010072403 hydroxyphenylacetyl-methyltyrosyl-phenylalanyl-glutaminyl-asparaginyl-arginyl-prolyl-argininamide Proteins 0.000 claims description 3
PPHTXRNHTVLQED-UHFFFAOYSA-N lixivaptan Chemical compound CC1=CC=C(F)C=C1C(=O)NC(C=C1Cl)=CC=C1C(=O)N1C2=CC=CC=C2CN2C=CC=C2C1 PPHTXRNHTVLQED-UHFFFAOYSA-N 0.000 claims description 3
229950000546 mozavaptan Drugs 0.000 claims description 3
239000002756 mu opiate receptor agonist Substances 0.000 claims description 3
210000004877 mucosa Anatomy 0.000 claims description 3
ICRPTZMWRJGNQI-CLIDGEQKSA-N n-[4-[(5z)-5-[2-[4-(dimethylamino)piperidin-1-yl]-2-oxoethylidene]-4,4-difluoro-2,3-dihydro-1-benzazepine-1-carbonyl]phenyl]-2-phenylbenzamide Chemical compound C1CC(N(C)C)CCN1C(=O)\C=C\1C(F)(F)CCN(C(=O)C=2C=CC(NC(=O)C=3C(=CC=CC=3)C=3C=CC=CC=3)=CC=2)C2=CC=CC=C2/1 ICRPTZMWRJGNQI-CLIDGEQKSA-N 0.000 claims description 3
108010010478 neurokinin A(4-10) Proteins 0.000 claims description 3
DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 claims description 3
229950009875 osanetant Drugs 0.000 claims description 3
206010039083 rhinitis Diseases 0.000 claims description 3
231100000046 skin rash Toxicity 0.000 claims description 3
230000009885 systemic effect Effects 0.000 claims description 3
WCZBBVLCJJAASE-UHFFFAOYSA-N (2,3-dihydroxy-4-methoxyphenyl)-(3,4,5-trimethoxyphenyl)methanone Chemical compound OC1=C(O)C(OC)=CC=C1C(=O)C1=CC(OC)=C(OC)C(OC)=C1 WCZBBVLCJJAASE-UHFFFAOYSA-N 0.000 claims description 2
DKXDSAPUJMKFEW-HWKKFYSMSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)CC(N)=O)C1=CC=CC=C1 DKXDSAPUJMKFEW-HWKKFYSMSA-N 0.000 claims description 2
UMTDAKAAYOXIKU-HXUWFJFHSA-N (2s)-n-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide Chemical group COC1=CC=CC=C1N1CCN(C[C@@H](C(=O)NC(C)(C)C)C=2C=CC=CC=2)CC1 UMTDAKAAYOXIKU-HXUWFJFHSA-N 0.000 claims description 2
WRPLGMBDXVBPEG-VGXZEHLRSA-N (2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pen Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 WRPLGMBDXVBPEG-VGXZEHLRSA-N 0.000 claims description 2
HMHYXLVEFVGOPM-QKUYTOGTSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutan Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C1=CC=CC=C1 HMHYXLVEFVGOPM-QKUYTOGTSA-N 0.000 claims description 2
GKHUUKGUNNYVGB-RAJBGOKPSA-N (4R,4aR,6E,7aR,12bR)-6-benzylidene-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.Oc1ccc2C[C@H]3N(CC4CC4)CC[C@]45[C@@H](Oc1c24)C(=O)\C(C[C@]35O)=C\c1ccccc1 GKHUUKGUNNYVGB-RAJBGOKPSA-N 0.000 claims description 2
VIAIHLLKDJKEKM-DCBBKWFGSA-N (4r,4as,7e,7ar,12bs)-7-[(e)-[(4r,4as,7ar,12bs)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ylidene]hydrazinylidene]-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a Chemical compound Cl.Cl.C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 VIAIHLLKDJKEKM-DCBBKWFGSA-N 0.000 claims description 2
PZWWYAHWHHNCHO-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 PZWWYAHWHHNCHO-FGHAYEPSSA-N 0.000 claims description 2
OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 claims description 2
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
XAXNKAGAUFXFDO-JVJDXIHNSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-chlorophenyl)prop-2-enamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)NC(=O)\C=C\C=2C=CC(Cl)=CC=2)CC1)O)CC1CC1 XAXNKAGAUFXFDO-JVJDXIHNSA-N 0.000 claims description 2
UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
BIVZVSIMVXNTKY-UHFFFAOYSA-N 2-(1-benzofuran-4-yl)acetamide Chemical compound NC(=O)CC1=CC=CC2=C1C=CO2 BIVZVSIMVXNTKY-UHFFFAOYSA-N 0.000 claims description 2
KTAIMVIYPUJRRA-UHFFFAOYSA-N 2-(1-benzothiophen-4-yl)acetamide Chemical compound NC(=O)CC1=CC=CC2=C1C=CS2 KTAIMVIYPUJRRA-UHFFFAOYSA-N 0.000 claims description 2
OFNGPKCQCHBFRA-TUYUPMGOSA-N 2-(3,4-dichlorophenyl)-n-[(1s,2s)-5-methoxy-2-pyrrolidin-1-yl-1,2,3,4-tetrahydronaphthalen-1-yl]-n-methylacetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.N1([C@@H]2[C@H](C=3C=CC=C(C=3CC2)OC)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CCCC1 OFNGPKCQCHBFRA-TUYUPMGOSA-N 0.000 claims description 2
FHEZDPDAYTVKKG-JLBKCEDKSA-N 2-(3,4-dichlorophenyl)-n-methyl-n-[(5r,7s,8s)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C[C@]21CCCO2 FHEZDPDAYTVKKG-JLBKCEDKSA-N 0.000 claims description 2
QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 claims description 2
XHWDVRRNQHMAPE-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[5-amino-2-[[5-amino-2-[[1-[6-amino-2-[[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpro Chemical compound C=1C=CC=CC=1CC(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1N(CCC1)C(=O)C(CCCCN)NC(=O)C1N(CCC1)C(=O)C(N)CCCN=C(N)N)C(=O)NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(O)=O)CC1=CC=CC=C1 XHWDVRRNQHMAPE-UHFFFAOYSA-N 0.000 claims description 2
108091005478 5-HT1 receptors Proteins 0.000 claims description 2
102000035038 5-HT1 receptors Human genes 0.000 claims description 2
102000035037 5-HT3 receptors Human genes 0.000 claims description 2
MBYSTKNEMJZSIK-UHFFFAOYSA-N 6-chloro-3-methyl-9-(3-methylbut-2-enoxy)-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C1CN(C)CCC2=C(Cl)C=CC(OCC=C(C)C)=C21 MBYSTKNEMJZSIK-UHFFFAOYSA-N 0.000 claims description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 2
108010031480 Artificial Receptors Proteins 0.000 claims description 2
108010024976 Asparaginase Proteins 0.000 claims description 2
102000015790 Asparaginase Human genes 0.000 claims description 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
108010006654 Bleomycin Proteins 0.000 claims description 2
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
102000053642 Catalytic RNA Human genes 0.000 claims description 2
108090000994 Catalytic RNA Proteins 0.000 claims description 2
241000251730 Chondrichthyes Species 0.000 claims description 2
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims description 2
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
108010036949 Cyclosporine Proteins 0.000 claims description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
108700012194 D-phenylalanyl-D-phenylalanyl-D-norleucyl-N-(4-pyridinylmethyl)- D-argininamide Proteins 0.000 claims description 2
102400000240 Dynorphin A(1-8) Human genes 0.000 claims description 2
101800001278 Dynorphin A(1-8) Proteins 0.000 claims description 2
108010020289 FE 200666 Proteins 0.000 claims description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
108010000817 Leuprolide Proteins 0.000 claims description 2
229930192392 Mitomycin Natural products 0.000 claims description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
150000001204 N-oxides Chemical class 0.000 claims description 2
229930012538 Paclitaxel Natural products 0.000 claims description 2
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
101800000684 Ribonuclease H Proteins 0.000 claims description 2
108700012920 TNF Proteins 0.000 claims description 2
102100039365 Tachykinin-4 Human genes 0.000 claims description 2
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
241000473945 Theria <moth genus> Species 0.000 claims description 2
108091023040 Transcription factor Proteins 0.000 claims description 2
102000040945 Transcription factor Human genes 0.000 claims description 2
RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 2
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
108020005202 Viral DNA Proteins 0.000 claims description 2
229930003427 Vitamin E Natural products 0.000 claims description 2
229960004150 aciclovir Drugs 0.000 claims description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
229940009456 adriamycin Drugs 0.000 claims description 2
229960005310 aldesleukin Drugs 0.000 claims description 2
108700025316 aldesleukin Proteins 0.000 claims description 2
229960000548 alemtuzumab Drugs 0.000 claims description 2
229960000473 altretamine Drugs 0.000 claims description 2
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
229960003805 amantadine Drugs 0.000 claims description 2
229960002932 anastrozole Drugs 0.000 claims description 2
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
230000000692 anti-sense effect Effects 0.000 claims description 2
239000000074 antisense oligonucleotide Substances 0.000 claims description 2
238000012230 antisense oligonucleotides Methods 0.000 claims description 2
229950006325 apadoline Drugs 0.000 claims description 2
JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical compound C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 claims description 2
229960003272 asparaginase Drugs 0.000 claims description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
229960002170 azathioprine Drugs 0.000 claims description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 2
108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 2
229960000997 bicalutamide Drugs 0.000 claims description 2
229960001561 bleomycin Drugs 0.000 claims description 2
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
229960001467 bortezomib Drugs 0.000 claims description 2
229960002092 busulfan Drugs 0.000 claims description 2
210000004900 c-terminal fragment Anatomy 0.000 claims description 2
229960004562 carboplatin Drugs 0.000 claims description 2
PSPANKCQVWSVHM-OUDZLNJNSA-N chembl55305 Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C5N(C3=CC=CC=C32)CC=2C=CC=CC=2)O)CC1)O)CC1CC1 PSPANKCQVWSVHM-OUDZLNJNSA-N 0.000 claims description 2
229960001265 ciclosporin Drugs 0.000 claims description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
229960004316 cisplatin Drugs 0.000 claims description 2
239000003246 corticosteroid Substances 0.000 claims description 2
229960001334 corticosteroids Drugs 0.000 claims description 2
239000004148 curcumin Substances 0.000 claims description 2
229940109262 curcumin Drugs 0.000 claims description 2
235000012754 curcumin Nutrition 0.000 claims description 2
125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 2
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
229930182912 cyclosporin Natural products 0.000 claims description 2
INUCRGMCKDQKNA-CEMLEFRQSA-N cyprodime Chemical compound N1([C@@H]2CC=3C=CC=C(C=3[C@@]3([C@]2(CCC(=O)C3)OC)CC1)OC)CC1CC1 INUCRGMCKDQKNA-CEMLEFRQSA-N 0.000 claims description 2
229960000684 cytarabine Drugs 0.000 claims description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
229960000975 daunorubicin Drugs 0.000 claims description 2
VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
229960003668 docetaxel Drugs 0.000 claims description 2
229960004679 doxorubicin Drugs 0.000 claims description 2
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
229960001433 erlotinib Drugs 0.000 claims description 2
229960001842 estramustine Drugs 0.000 claims description 2
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 2
229960005420 etoposide Drugs 0.000 claims description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
MVKIWCDXKCUDEH-QFIPXVFZSA-N fedotozine Chemical compound C([C@](CC)(N(C)C)C=1C=CC=CC=1)OCC1=CC(OC)=C(OC)C(OC)=C1 MVKIWCDXKCUDEH-QFIPXVFZSA-N 0.000 claims description 2
229950008449 fedotozine Drugs 0.000 claims description 2
229960002949 fluorouracil Drugs 0.000 claims description 2
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
229960002074 flutamide Drugs 0.000 claims description 2
229960003692 gamma aminobutyric acid Drugs 0.000 claims description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
229960002584 gefitinib Drugs 0.000 claims description 2
229960000578 gemtuzumab Drugs 0.000 claims description 2
229940080856 gleevec Drugs 0.000 claims description 2
239000003966 growth inhibitor Substances 0.000 claims description 2
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 2
229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
229960000908 idarubicin Drugs 0.000 claims description 2
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
229960001101 ifosfamide Drugs 0.000 claims description 2
229960002411 imatinib Drugs 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
229940124524 integrase inhibitor Drugs 0.000 claims description 2
239000002850 integrase inhibitor Substances 0.000 claims description 2
229940079322 interferon Drugs 0.000 claims description 2
229960004768 irinotecan Drugs 0.000 claims description 2
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
150000002540 isothiocyanates Chemical class 0.000 claims description 2
229960001627 lamivudine Drugs 0.000 claims description 2
JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 2
229960003881 letrozole Drugs 0.000 claims description 2
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
229960004338 leuprorelin Drugs 0.000 claims description 2
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims description 2
229960004961 mechlorethamine Drugs 0.000 claims description 2
229960001786 megestrol Drugs 0.000 claims description 2
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
229960001924 melphalan Drugs 0.000 claims description 2
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
229960003105 metformin Drugs 0.000 claims description 2
LRPCLTPZMUIPFK-UHFFFAOYSA-N methane;sulfuric acid Chemical compound C.OS(O)(=O)=O LRPCLTPZMUIPFK-UHFFFAOYSA-N 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
229960004857 mitomycin Drugs 0.000 claims description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
229960001156 mitoxantrone Drugs 0.000 claims description 2
ZHVWWEYETMPAMX-IFKAHUTRSA-N naltriben Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3OC=25)O)CC1)O)CC1CC1 ZHVWWEYETMPAMX-IFKAHUTRSA-N 0.000 claims description 2
108010054552 neurokinin B (4-10) Proteins 0.000 claims description 2
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 2
229960002653 nilutamide Drugs 0.000 claims description 2
229960001592 paclitaxel Drugs 0.000 claims description 2
229960001744 pegaspargase Drugs 0.000 claims description 2
108010001564 pegaspargase Proteins 0.000 claims description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
108700040302 phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide Proteins 0.000 claims description 2
RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 claims description 2
KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 claims description 2
229960000471 pleconaril Drugs 0.000 claims description 2
229960003171 plicamycin Drugs 0.000 claims description 2
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
229960000624 procarbazine Drugs 0.000 claims description 2
229960000329 ribavirin Drugs 0.000 claims description 2
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
108091092562 ribozyme Proteins 0.000 claims description 2
229960000888 rimantadine Drugs 0.000 claims description 2
SWJFAAOLULPTRH-XOGXUEEYSA-N sdm25n Chemical compound O.Cl.N1C2=CC=CC=C2C(C[C@]23O)=C1[C@H](O1)[C@]42CCN(CC(=C)C)C3CC2=CC=C(O)C1=C42 SWJFAAOLULPTRH-XOGXUEEYSA-N 0.000 claims description 2
108010016070 senktide Proteins 0.000 claims description 2
108010006590 serotonin 5 receptor Proteins 0.000 claims description 2
WKXSXFYQPCWZOS-UHFFFAOYSA-N skf 104856 Chemical compound C1N(C)CCC2=C(Cl)C=CC3=C2C1=C(C=C)S3 WKXSXFYQPCWZOS-UHFFFAOYSA-N 0.000 claims description 2
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 2
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 2
229950011332 talnetant Drugs 0.000 claims description 2
229960001603 tamoxifen Drugs 0.000 claims description 2
230000008685 targeting Effects 0.000 claims description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
229960004964 temozolomide Drugs 0.000 claims description 2
229960003604 testosterone Drugs 0.000 claims description 2
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
229960000303 topotecan Drugs 0.000 claims description 2
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
229960000575 trastuzumab Drugs 0.000 claims description 2
RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 2
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 2
229960004824 triptorelin Drugs 0.000 claims description 2
229960003048 vinblastine Drugs 0.000 claims description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
229960004528 vincristine Drugs 0.000 claims description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
229960002066 vinorelbine Drugs 0.000 claims description 2
229940046009 vitamin E Drugs 0.000 claims description 2
235000019165 vitamin E Nutrition 0.000 claims description 2
239000011709 vitamin E Substances 0.000 claims description 2
WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
229960000237 vorinostat Drugs 0.000 claims description 2
ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
229960001028 zanamivir Drugs 0.000 claims description 2
208000023275 Autoimmune disease Diseases 0.000 claims 3
208000020685 sleep-wake disease Diseases 0.000 claims 3
229960005486 vaccine Drugs 0.000 claims 3
QVQOGNOOAMQKCE-OVSZNHMYSA-N (2r)-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(10r,13s,16s,19s,22r)-13-(2-amino-2-oxoethyl)-16-(3-amino-3-oxopropyl)-19-benzyl-22-[(4-methoxyphenyl)methyl]-12,15,18,21,24-pentaoxo-7,8-dithia-11,14,17,20,23-pen Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@H](CCC2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)CSSC2(CCCCC2)CC(=O)N1 QVQOGNOOAMQKCE-OVSZNHMYSA-N 0.000 claims 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
108700005160 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine- vasopressin Proteins 0.000 claims 2
108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims 2
108010045937 Felypressin Proteins 0.000 claims 2
208000032319 Primary lateral sclerosis Diseases 0.000 claims 2
206010046298 Upper motor neurone lesion Diseases 0.000 claims 2
241000700605 Viruses Species 0.000 claims 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
JGBBVDFNZSRLIF-UHFFFAOYSA-N conivaptan Chemical compound C12=CC=CC=C2C=2[N]C(C)=NC=2CCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=CC=C1 JGBBVDFNZSRLIF-UHFFFAOYSA-N 0.000 claims 2
230000007812 deficiency Effects 0.000 claims 2
229960004281 desmopressin Drugs 0.000 claims 2
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims 2
SFKQVVDKFKYTNA-DZCXQCEKSA-N felypressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](N)CSSC1 SFKQVVDKFKYTNA-DZCXQCEKSA-N 0.000 claims 2
229960001527 felypressin Drugs 0.000 claims 2
230000002458 infectious effect Effects 0.000 claims 2
208000002551 irritable bowel syndrome Diseases 0.000 claims 2
201000010901 lateral sclerosis Diseases 0.000 claims 2
208000005264 motor neuron disease Diseases 0.000 claims 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
VZBKOBSSEVXFNF-QIRDZIKRSA-N 1-[4-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1h-triazol-1-ium-5-yl]-n,n-dimethylmethanamine;chloride Chemical compound Cl.O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNN=C1CN(C)C VZBKOBSSEVXFNF-QIRDZIKRSA-N 0.000 claims 1
PFGPGGNXKZBICE-ARJAWSKDSA-N 2-methoxy-5-[(z)-2-(7-methoxy-1,3-benzodioxol-5-yl)ethenyl]aniline Chemical compound C=1C=2OCOC=2C(OC)=CC=1\C=C/C1=CC=C(OC)C(N)=C1 PFGPGGNXKZBICE-ARJAWSKDSA-N 0.000 claims 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 1
208000026872 Addison Disease Diseases 0.000 claims 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
241000894006 Bacteria Species 0.000 claims 1
208000009137 Behcet syndrome Diseases 0.000 claims 1
201000002829 CREST Syndrome Diseases 0.000 claims 1
241000606161 Chlamydia Species 0.000 claims 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
208000015943 Coeliac disease Diseases 0.000 claims 1
206010009900 Colitis ulcerative Diseases 0.000 claims 1
206010010356 Congenital anomaly Diseases 0.000 claims 1
208000011231 Crohn disease Diseases 0.000 claims 1
206010014561 Emphysema Diseases 0.000 claims 1
201000009273 Endometriosis Diseases 0.000 claims 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
241000233866 Fungi Species 0.000 claims 1
208000024869 Goodpasture syndrome Diseases 0.000 claims 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
208000003807 Graves Disease Diseases 0.000 claims 1
208000015023 Graves' disease Diseases 0.000 claims 1
208000031886 HIV Infections Diseases 0.000 claims 1
208000037357 HIV infectious disease Diseases 0.000 claims 1
208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
108010034145 Helminth Proteins Proteins 0.000 claims 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
208000035150 Hypercholesterolemia Diseases 0.000 claims 1
206010067972 Interstitial granulomatous dermatitis Diseases 0.000 claims 1
206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
206010034277 Pemphigoid Diseases 0.000 claims 1
208000031845 Pernicious anaemia Diseases 0.000 claims 1
206010034912 Phobia Diseases 0.000 claims 1
206010065159 Polychondritis Diseases 0.000 claims 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
241000606701 Rickettsia Species 0.000 claims 1
240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
206010039710 Scleroderma Diseases 0.000 claims 1
102000000344 Sirtuin 1 Human genes 0.000 claims 1
108010041191 Sirtuin 1 Proteins 0.000 claims 1
208000021386 Sjogren Syndrome Diseases 0.000 claims 1
201000006704 Ulcerative Colitis Diseases 0.000 claims 1
206010047115 Vasculitis Diseases 0.000 claims 1
208000029560 autism spectrum disease Diseases 0.000 claims 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
206010071572 autoimmune progesterone dermatitis Diseases 0.000 claims 1
125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
210000004027 cell Anatomy 0.000 claims 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
229960001653 citalopram Drugs 0.000 claims 1
208000018631 connective tissue disease Diseases 0.000 claims 1
239000013256 coordination polymer Substances 0.000 claims 1
201000001981 dermatomyositis Diseases 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
230000007613 environmental effect Effects 0.000 claims 1
229960004341 escitalopram Drugs 0.000 claims 1
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 1
229960002464 fluoxetine Drugs 0.000 claims 1
229960004038 fluvoxamine Drugs 0.000 claims 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
208000019622 heart disease Diseases 0.000 claims 1
244000000013 helminth Species 0.000 claims 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
208000006575 hypertriglyceridemia Diseases 0.000 claims 1
229960003444 immunosuppressant agent Drugs 0.000 claims 1
230000001861 immunosuppressant effect Effects 0.000 claims 1
239000003018 immunosuppressive agent Substances 0.000 claims 1
208000006132 lipodystrophy Diseases 0.000 claims 1
206010025135 lupus erythematosus Diseases 0.000 claims 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
206010028417 myasthenia gravis Diseases 0.000 claims 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
230000004770 neurodegeneration Effects 0.000 claims 1
239000003402 opiate agonist Substances 0.000 claims 1
244000045947 parasite Species 0.000 claims 1
229960002296 paroxetine Drugs 0.000 claims 1
208000005987 polymyositis Diseases 0.000 claims 1
230000008569 process Effects 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 1
229960003770 reboxetine Drugs 0.000 claims 1
206010039073 rheumatoid arthritis Diseases 0.000 claims 1
201000000306 sarcoidosis Diseases 0.000 claims 1
239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
229960002073 sertraline Drugs 0.000 claims 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
230000001568 sexual effect Effects 0.000 claims 1
208000009174 transverse myelitis Diseases 0.000 claims 1
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
229960004688 venlafaxine Drugs 0.000 claims 1
108010015889 zeta receptor Proteins 0.000 claims 1
230000036651 mood Effects 0.000 description 43
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 28
101800005049 Beta-endorphin Proteins 0.000 description 19
102100027467 Pro-opiomelanocortin Human genes 0.000 description 19
WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 19
238000001727 in vivo Methods 0.000 description 19
230000004048 modification Effects 0.000 description 19
238000012986 modification Methods 0.000 description 19
229940127240 opiate Drugs 0.000 description 17
229960005181 morphine Drugs 0.000 description 16
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
230000000994 depressogenic effect Effects 0.000 description 12
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 12
206010015535 Euphoric mood Diseases 0.000 description 11
101800000414 Corticotropin Proteins 0.000 description 10
241001539473 Euphoria Species 0.000 description 10
101000895481 Homo sapiens Corticoliberin Proteins 0.000 description 10
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 10
239000000935 antidepressant agent Substances 0.000 description 10
210000003169 central nervous system Anatomy 0.000 description 10
229960000258 corticotropin Drugs 0.000 description 10
230000003247 decreasing effect Effects 0.000 description 10
108700023159 delta Opioid Receptors Proteins 0.000 description 10
102000048124 delta Opioid Receptors Human genes 0.000 description 10
230000001976 improved effect Effects 0.000 description 10
210000004556 brain Anatomy 0.000 description 9
KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
102400000739 Corticotropin Human genes 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
241000700159 Rattus Species 0.000 description 7
230000001154 acute effect Effects 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 7
230000006870 function Effects 0.000 description 7
229960000890 hydrocortisone Drugs 0.000 description 7
102000051367 mu Opioid Receptors Human genes 0.000 description 7
239000008177 pharmaceutical agent Substances 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
210000000225 synapse Anatomy 0.000 description 7
108020001612 μ-opioid receptors Proteins 0.000 description 7
IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical class C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 description 6
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
208000020401 Depressive disease Diseases 0.000 description 6
230000009471 action Effects 0.000 description 6
230000008499 blood brain barrier function Effects 0.000 description 6
210000001218 blood-brain barrier Anatomy 0.000 description 6
229910052799 carbon Inorganic materials 0.000 description 6
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
238000010304 firing Methods 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000003938 response to stress Effects 0.000 description 6
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 5
108010040718 Neurokinin-1 Receptors Proteins 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
229940005513 antidepressants Drugs 0.000 description 5
230000008859 change Effects 0.000 description 5
GBONBLHJMVUBSJ-FAUHKOHMSA-N corticorelin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)C1=CNC=N1 GBONBLHJMVUBSJ-FAUHKOHMSA-N 0.000 description 5
229960002069 diamorphine Drugs 0.000 description 5
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 5
230000006872 improvement Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000006215 rectal suppository Substances 0.000 description 5
229940100618 rectal suppository Drugs 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
230000032258 transport Effects 0.000 description 5
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
108010092674 Enkephalins Proteins 0.000 description 4
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
102000002002 Neurokinin-1 Receptors Human genes 0.000 description 4
108010040722 Neurokinin-2 Receptors Proteins 0.000 description 4
102100037342 Substance-K receptor Human genes 0.000 description 4
229930186949 TCA Natural products 0.000 description 4
229940123445 Tricyclic antidepressant Drugs 0.000 description 4
208000021017 Weight Gain Diseases 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
231100000987 absorbed dose Toxicity 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
230000006399 behavior Effects 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
230000036515 potency Effects 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
108010040716 Neurokinin-3 Receptors Proteins 0.000 description 3
102000002003 Neurokinin-3 Receptors Human genes 0.000 description 3
208000004550 Postoperative Pain Diseases 0.000 description 3
102000004659 Presynaptic Receptors Human genes 0.000 description 3
108010003717 Presynaptic Receptors Proteins 0.000 description 3
229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 3
230000004913 activation Effects 0.000 description 3
210000004198 anterior pituitary gland Anatomy 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
125000003636 chemical group Chemical group 0.000 description 3
230000037326 chronic stress Effects 0.000 description 3
229960004126 codeine Drugs 0.000 description 3
IKENVDNFQMCRTR-UHFFFAOYSA-N conivaptan Chemical compound C12=CC=CC=C2C=2NC(C)=NC=2CCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=CC=C1 IKENVDNFQMCRTR-UHFFFAOYSA-N 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
230000001544 dysphoric effect Effects 0.000 description 3
235000005686 eating Nutrition 0.000 description 3
230000037406 food intake Effects 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
108091008042 inhibitory receptors Proteins 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
230000003533 narcotic effect Effects 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
229940005483 opioid analgesics Drugs 0.000 description 3
229940124583 pain medication Drugs 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
SVZZBABSMGVXHM-LZWOXQAQSA-N (1R,9R,10R)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-6-ol Chemical class C1CCC[C@H]2[C@]3([H])NCC[C@@]21C1=CC=CC(O)=C1C3 SVZZBABSMGVXHM-LZWOXQAQSA-N 0.000 description 2
KQWVAUSXZDRQPZ-UMTXDNHDSA-N 4-[(R)-[(2S,5R)-2,5-dimethyl-4-prop-2-enyl-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1[C@H](C=1C=C(OC)C=CC=1)N1[C@@H](C)CN(CC=C)[C@H](C)C1 KQWVAUSXZDRQPZ-UMTXDNHDSA-N 0.000 description 2
108091005479 5-HT2 receptors Proteins 0.000 description 2
101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 2
101000957708 Catostomus commersonii Corticoliberin-2 Proteins 0.000 description 2
206010011953 Decreased activity Diseases 0.000 description 2
OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 description 2
206010013954 Dysphoria Diseases 0.000 description 2
208000033618 Elevated mood Diseases 0.000 description 2
102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 2
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
101000895495 Rattus norvegicus Corticoliberin Proteins 0.000 description 2
241001136613 Salvia divinorum Species 0.000 description 2
208000013200 Stress disease Diseases 0.000 description 2
102000003141 Tachykinin Human genes 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
229940068372 acetyl salicylate Drugs 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000002269 analeptic agent Substances 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000003759 clinical diagnosis Methods 0.000 description 2
230000007012 clinical effect Effects 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000002222 downregulating effect Effects 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
230000002964 excitative effect Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
229960002428 fentanyl Drugs 0.000 description 2
PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 description 2
229960002053 flibanserin Drugs 0.000 description 2
229960000389 fluoxetine hydrochloride Drugs 0.000 description 2
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
229960000240 hydrocodone Drugs 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000000945 opiatelike Effects 0.000 description 2
QEEJLLNYQOBRRM-KSHGRFHLSA-N ovine crf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 QEEJLLNYQOBRRM-KSHGRFHLSA-N 0.000 description 2
229960002085 oxycodone Drugs 0.000 description 2
230000037324 pain perception Effects 0.000 description 2
230000008058 pain sensation Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
230000035479 physiological effects, processes and functions Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 description 2
239000003488 releasing hormone Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
230000026416 response to pain Effects 0.000 description 2
208000012201 sexual and gender identity disease Diseases 0.000 description 2
208000015891 sexual disease Diseases 0.000 description 2
230000007958 sleep Effects 0.000 description 2
230000016160 smooth muscle contraction Effects 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
108060008037 tachykinin Proteins 0.000 description 2
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
230000008733 trauma Effects 0.000 description 2
229960004799 tryptophan Drugs 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
SEJUQQOPVAUETF-QHLBDZCJSA-N (2r,6r,11s)-3-(cyclopropylmethyl)-6-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2h)-one Chemical compound C([C@@]1([C@@H]([C@@H]2C(=O)C=3C1=CC(O)=CC=3)C)CC)CN2CC1CC1 SEJUQQOPVAUETF-QHLBDZCJSA-N 0.000 description 1
SBBYBXSFWOLDDG-JLTOFOAXSA-N (2s)-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperazine-1-carboxamide Chemical compound C1([C@H]2CNCCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=CC=C(F)C=C1C SBBYBXSFWOLDDG-JLTOFOAXSA-N 0.000 description 1
JNJFKTKRRMLCEB-GMIGKAJZSA-N (4r,4ar,7as,12bs)-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-9-ol Chemical compound C([C@@H]1O2)C=C[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(O)=CC=C1C4 JNJFKTKRRMLCEB-GMIGKAJZSA-N 0.000 description 1
HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
OZGOGGDEMRNDIJ-UHFFFAOYSA-N 2-acetyloxybenzoic acid;2-aminobenzoic acid Chemical compound NC1=CC=CC=C1C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O OZGOGGDEMRNDIJ-UHFFFAOYSA-N 0.000 description 1
125000001431 2-aminoisobutyric acid group Chemical group [#6]C([#6])(N*)C(*)=O 0.000 description 1
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
241000272517 Anseriformes Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101000895475 Bos taurus Corticoliberin Proteins 0.000 description 1
108091005471 CRHR1 Proteins 0.000 description 1
108091005470 CRHR2 Proteins 0.000 description 1
101100353046 Caenorhabditis elegans mig-6 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
102100038796 E3 ubiquitin-protein ligase TRIM13 Human genes 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
108010041652 GR 73632 Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
208000001613 Gambling Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
241000699694 Gerbillinae Species 0.000 description 1
101150104779 HTR2A gene Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
101000664589 Homo sapiens E3 ubiquitin-protein ligase TRIM13 Proteins 0.000 description 1
101001122476 Homo sapiens Mu-type opioid receptor Proteins 0.000 description 1
101150013372 Htr2c gene Proteins 0.000 description 1
108010070424 ICI 174865 Proteins 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
RBKYMAQIAMFDOE-CQJMVLFOSA-N L-Phe-L-Phe-Gly-L-Leu-L-Met-NH2 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBKYMAQIAMFDOE-CQJMVLFOSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
241000207923 Lamiaceae Species 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
102000010909 Monoamine Oxidase Human genes 0.000 description 1
108010062431 Monoamine oxidase Proteins 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
102100028647 Mu-type opioid receptor Human genes 0.000 description 1
DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
102000002188 Neurokinin NK1 receptors Human genes 0.000 description 1
108050009554 Neurokinin NK1 receptors Proteins 0.000 description 1
102000001490 Opioid Peptides Human genes 0.000 description 1
108010093625 Opioid Peptides Proteins 0.000 description 1
208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
235000011771 Salvia divinorum Nutrition 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
102100037346 Substance-P receptor Human genes 0.000 description 1
206010042458 Suicidal ideation Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
NPGABYHTDVGGJK-UHFFFAOYSA-N Tifluadom Chemical compound C1N=C(C=2C(=CC=CC=2)F)C2=CC=CC=C2N(C)C1CNC(=O)C=1C=CSC=1 NPGABYHTDVGGJK-UHFFFAOYSA-N 0.000 description 1
VQLPLYSROCPWFF-QZTJIDSGSA-N U50488 Chemical compound N1([C@@H]2CCCC[C@H]2N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)CCCC1 VQLPLYSROCPWFF-QZTJIDSGSA-N 0.000 description 1
101710095160 Urotensin-1 Proteins 0.000 description 1
229940122740 VLA antagonist Drugs 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
208000017515 adrenocortical insufficiency Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
FUOOLUPWFVMBKG-UHFFFAOYSA-N alpha-amino-isobutyric acid Natural products CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940124977 antiviral medication Drugs 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
229960001372 aprepitant Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000005821 brain abnormality Effects 0.000 description 1
ZDXGFIXMPOUDFF-XLIONFOSSA-N bremazocine Chemical compound C([C@]1(C2=CC(O)=CC=C2C[C@@H]2C1(C)C)CC)CN2CC1(O)CC1 ZDXGFIXMPOUDFF-XLIONFOSSA-N 0.000 description 1
229950008841 bremazocine Drugs 0.000 description 1
XIGAHNVCEFUYOV-UHFFFAOYSA-N but-2-enedioic acid;n-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-n-pyridin-2-ylcyclohexanecarboxamide Chemical compound OC(=O)C=CC(O)=O.COC1=CC=CC=C1N1CCN(CCN(C(=O)C2CCCCC2)C=2N=CC=CC=2)CC1 XIGAHNVCEFUYOV-UHFFFAOYSA-N 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 description 1
229950004689 carfentanil Drugs 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
KFUIXDNQSMKKJQ-ZLFMSJRASA-N chembl439883 Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)CNC(=O)[C@H]2NC(=O)CC2)CCC1 KFUIXDNQSMKKJQ-ZLFMSJRASA-N 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
BTYHAFSDANBVMJ-UHFFFAOYSA-N conivaptan hydrochloride Chemical compound Cl.C12=CC=CC=C2C=2NC(C)=NC=2CCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=CC=C1 BTYHAFSDANBVMJ-UHFFFAOYSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229950002213 cyclazocine Drugs 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000000881 depressing effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
229950002494 diprenorphine Drugs 0.000 description 1
229930004069 diterpene Natural products 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
238000002283 elective surgery Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
230000008029 eradication Effects 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000023611 glucuronidation Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000001127 hyperphagic effect Effects 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
229940039009 isoproterenol Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000007056 liver toxicity Effects 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000006241 metabolic reaction Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
229960001785 mirtazapine Drugs 0.000 description 1
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical compound C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
IHDRUIHIJWCTIY-JOCHJYFZSA-N n-[(2r)-5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl]-4-morpholin-4-ylbenzamide Chemical compound C1CN(C)CCN1C1=CC=C(C)C2=C1C[C@H](NC(=O)C=1C=CC(=CC=1)N1CCOCC1)CC2 IHDRUIHIJWCTIY-JOCHJYFZSA-N 0.000 description 1
229960000938 nalorphine Drugs 0.000 description 1
108010081490 naloxone receptor Proteins 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
230000009125 negative feedback regulation Effects 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
AOCUKGFDRUSDQH-PIKKTMSISA-N ocrf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)CC)[C@@H](C)O)C(C)C)C(C)O)C1=CNC=N1 AOCUKGFDRUSDQH-PIKKTMSISA-N 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
239000003399 opiate peptide Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000008289 pathophysiological mechanism Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000004344 phenylpropyl group Chemical group 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
LEWDKQKVAFOMPI-UHFFFAOYSA-N quinoline-4-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=CC=NC2=C1 LEWDKQKVAFOMPI-UHFFFAOYSA-N 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
108010086511 sauvagine Proteins 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
230000003997 social interaction Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
NYKCGQQJNVPOLU-ONTIZHBOSA-N spiradoline Chemical compound C([C@@H]([C@H](C1)N2CCCC2)N(C)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C[C@]21CCCO2 NYKCGQQJNVPOLU-ONTIZHBOSA-N 0.000 description 1
229950006495 spiradoline Drugs 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
235000021286 stilbenes Nutrition 0.000 description 1
230000008939 stimulatory process Effects 0.000 description 1
108010017569 substance P (7-11) Proteins 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000002462 tachykinin receptor antagonist Substances 0.000 description 1
229950009989 tifluadom Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
229960005026 toremifene Drugs 0.000 description 1
229940054353 vaprisol Drugs 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229950007305 vestipitant Drugs 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2007221135A 2006-02-27 2007-02-27 Methods for regulating neurotransmitter systems by inducing counteradaptations Abandoned AU2007221135A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US77719006P	2006-02-27	2006-02-27
US60/777,190		2006-02-27
US85818606P	2006-11-09	2006-11-09
US60/858,186		2006-11-09
PCT/US2007/004959 WO2007100775A2 (fr)	2006-02-27	2007-02-27	Methodes de regulation des systemes neurotransmetteurs par induction de contre-adaptations

Publications (1)

Publication Number	Publication Date
AU2007221135A1 true AU2007221135A1 (en)	2007-09-07

Family

ID=38459618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2007221135A Abandoned AU2007221135A1 (en)	2006-02-27	2007-02-27	Methods for regulating neurotransmitter systems by inducing counteradaptations

Country Status (5)

Country	Link
EP (1)	EP2001495A4 (fr)
JP (1)	JP2009528289A (fr)
AU (1)	AU2007221135A1 (fr)
CA (1)	CA2643802A1 (fr)
WO (1)	WO2007100775A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000021509A2 (fr)	1998-10-15	2000-04-20	Imperial College Innovations Limited	Methodes therapeutiques
US9415107B2 (en) *	2005-11-10	2016-08-16	Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College	Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
GB0624282D0 (en)	2006-12-05	2007-01-10	Cavalla David	Treatment of cachexia
WO2009001764A1 (fr) *	2007-06-22	2008-12-31	Toray Industries, Inc.	Traitement ou prevention du syndrome du dysfonctionnement de l'integration
WO2009109001A1 (fr) *	2008-03-04	2009-09-11	Adelaide Research & Innovation Pty Ltd	Procédé de prévention et/ou de traitement d’une maladie, d’une condition ou d’un état associés à une fonction réduite des neurones dopaminergiques
WO2010074753A1 (fr)	2008-12-23	2010-07-01	Map Pharmaceuticals, Inc.	Dispositifs d'inhalation et procédés associés pour administration de composés hypnotiques sédatifs
CA2785056A1 (fr)	2009-12-22	2011-07-21	Pondera Biotechnologies, LLC	Methodes et compositions pour le traitement de la detresse dysfonctionnelle et l'augmentation de la securite et de l'efficacite de medicaments specifiques
KR20130135820A (ko)	2010-06-16	2013-12-11	엠베라 뉴로 테라퓨틱스 인코포레이티드	중독，정신 장애 및 신경퇴행성 질환 치료용 조성물 및 방법
US11000505B2 (en) *	2010-06-29	2021-05-11	The Trustees Of The University Of Pennsylvania	Salvinorin compositions and uses thereof
WO2012006178A1 (fr) *	2010-06-29	2012-01-12	The Trustees Of The University Of Pennsylvania	Compositions de salvinorine et leurs utilisations
DK2925757T3 (en)	2012-11-19	2018-01-15	Novartis Ag	Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en)	2012-11-19	2014-10-28	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
SG11201505517TA (en) *	2013-01-21	2015-09-29	Avant Derma Pte Ltd	Use of selective delta-opioid receptor antagonists and specific sensory receptor ligands
EP2948450A4 (fr) *	2013-01-28	2016-11-09	Viamet Pharmaceuticals Inc	Composés inhibiteurs de métalloenzyme
WO2014120936A2 (fr)	2013-01-30	2014-08-07	Pharmorx Therapeutics, Inc.	Traitement de la dépression et autres maladies avec un agent à faible dose
CA2909504C (fr) *	2013-04-17	2021-04-20	H. Lundbeck A/S	Nalmefene pour le traitement de patients atteints de trouble de l'humeur
TWI704933B (zh)	2013-10-07	2020-09-21	美商帝國製藥美國股份有限公司	右美托咪啶經皮輸送裝置及使用其之方法
TWI709417B (zh)	2013-10-07	2020-11-11	美商帝國製藥美國股份有限公司	使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
CN105764496B (zh)	2013-10-07	2020-09-25	帝国制药美国公司	用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
WO2016195723A1 (fr) *	2015-06-03	2016-12-08	Beller Pharmaceuticals LLC	Méthodes de traitement d'états médiés par la substance p
CN106008487B (zh)	2015-12-31	2019-08-09	北京理工大学	一种二苯乙烯类衍生物及其制备方法
WO2018102552A1 (fr)	2016-11-30	2018-06-07	Case Western Reserve University	Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
JP2020514323A (ja)	2017-02-06	2020-05-21	ケースウエスタンリザーブユニバーシティ	短鎖デヒドロゲナーゼ活性を調節する組成物と方法
BR112019018700A2 (pt)	2017-03-10	2020-04-07	Embera Neurotherapeutics Inc	composições farmacêuticas e seus usos
US10729693B2 (en) *	2018-03-02	2020-08-04	Ponce Medical School Foundation, Inc.	Compositions and methods for the treatment of endometriosis
EA202191422A1 (ru)	2018-11-21	2021-10-21	Кейс Вестерн Ризерв Юниверсити	Композиции и способы модулирования активности короткоцепочечной дегидрогеназы

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPP150098A0 (en) *	1998-01-27	1998-02-19	Fujisawa Pharmaceutical Co., Ltd.	Benzamide derivatives
TWI256309B (en) *	1999-10-13	2006-06-11	Akzo Nobel Nv	New formulation of mirtazapine
PL365955A1 (en) *	2000-07-19	2005-01-24	Bristol-Myers Squibb Pharma Company	Crf 2? ligands in combination therapy
US6437093B1 (en) *	2000-11-28	2002-08-20	Milkhaus Laboratory, Inc.	Methods of treatment comprising administration of Substance P
CA2476218A1 (fr) *	2002-02-08	2003-08-14	President And Fellows Of Harvard College	Composes therapeutiques
CA2580694A1 (fr) *	2004-09-23	2006-03-30	Alexander Michalow	Methodes permettant de reguler les systemes de neurotransmetteurs en induisant des contre-adaptations

2007
- 2007-02-27 CA CA002643802A patent/CA2643802A1/fr not_active Abandoned
- 2007-02-27 JP JP2008556468A patent/JP2009528289A/ja active Pending
- 2007-02-27 EP EP07751698A patent/EP2001495A4/fr not_active Withdrawn
- 2007-02-27 WO PCT/US2007/004959 patent/WO2007100775A2/fr not_active Ceased
- 2007-02-27 AU AU2007221135A patent/AU2007221135A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2007100775A2 (fr)	2007-09-07
CA2643802A1 (fr)	2007-09-07
WO2007100775A3 (fr)	2008-11-27
EP2001495A2 (fr)	2008-12-17
EP2001495A4 (fr)	2010-12-08
JP2009528289A (ja)	2009-08-06

Publication	Publication Date	Title
AU2007221135A1 (en)	2007-09-07	Methods for regulating neurotransmitter systems by inducing counteradaptations
US20100173926A1 (en)	2010-07-08	Methods for Regulating Neurotransmitter Systems by Inducing Counteradaptations
AU2005286733B2 (en)	2009-11-05	Methods for regulating neurotransmitter systems by inducing counteradaptations
Honore et al.	2006	A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl] amino}-2, 2-dimethylpropyl)-2-(3, 4-dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat
CN1104242C (zh)	2003-04-02	依匹斯汀在治疗疼痛中的用途
Bartolini et al.	2011	Analgesic and antineuropathic drugs acting through central cholinergic mechanisms
CN101432011A (zh)	2009-05-13	通过诱导逆适应调节神经递质系统的方法
EP2288345B1 (fr)	2015-06-10	Produits psycho-pharmaceutiques
Yamamoto et al.	2014	Involvement of substance P in the development of cisplatin‐induced acute and delayed pica in rats
JP2017119710A (ja)	2017-07-06	抗コネクシン剤としてのフレカイニドの使用、及び向精神薬の効果を増強する方法
Shinpo et al.	2012	The role of area postrema neurons expressing H-channels in the induction mechanism of nausea and vomiting
Heidbreder et al.	2004	ROLE OF DOPAMINE D
Levi et al.	2002	A review of chemical agents in the pharmacotherapy of addiction
US9023788B2 (en)	2015-05-05	Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
Rénéric et al.	2002	In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed
Mhatre et al.	2003	μ1-opioid antagonist naloxonazine alters ethanol discrimination and consumption
Li et al.	2003	Differential roles of spinal protein kinases C and a in development of primary heat and mechanical hypersensitivity induced by subcutaneous bee venom chemical injury in the rat
CN1767833A (zh)	2006-05-03	卡马西平衍生物在治疗痴呆患者的激动中的用途
EP1707202A1 (fr)	2006-10-04	Composes organiques
US20200352917A1 (en)	2020-11-12	Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
Liu et al.	2015	Design, synthesis, and evaluation of new endomorphin analogs with enhanced central antinociception after peripheral administration
Mehta et al.	2009	Acute pain management in opioid dependent patients
Hrnčić et al.	2009	Influence of NR2B-selective NMDA antagonist on lindane-induced seizures in rats
Yang et al.	2006	Vasopressin Produces Inhibition on Phrenic Nerve Activity and Apnea through V~ 1~ A Receptors in the Area Postrema in Rats
JP2005518429A (ja)	2005-06-23	認知機能障害の治療のためのニコチン受容体の調節因子の使用

Legal Events

Date	Code	Title	Description
2012-09-20	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application